With fears over manufacturing costs and future investment, here’s what firms are doing
Brexit poses a big threat to pharmaceutical research and manufacturing in the UK, the industry has warned, by driving up manufacturing costs and deterring future investment.
AstraZeneca and other companies have frozen all manufacturing investments. Britain’s second-biggest drugmaker decided to halt further investments at its Macclesfield site in the summer of 2017. Its chairman, Leif Johansson, has warned that the UK needs to make sure it “does not become an isolated island in the middle of the Atlantic Ocean.”